112 related articles for article (PubMed ID: 21556660)
1. The aberrant p53 protein (review).
Furihata M; Sonobe H; Ohtsuki Y
Int J Oncol; 1995 Jun; 6(6):1209-26. PubMed ID: 21556660
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of p53 protein in human tumors.
Inoue K; Kurabayashi A; Shuin T; Ohtsuki Y; Furihata M
Med Mol Morphol; 2012 Jun; 45(3):115-23. PubMed ID: 23001293
[TBL] [Abstract][Full Text] [Related]
3. Genetic pathways of two types of gastric cancer.
Tahara E
IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of oncogenes and tumor suppressor genes in human malignancy.
Spandidos DA; Liloglou T; Field JK
Stem Cells; 1993 May; 11(3):194-8. PubMed ID: 8318905
[TBL] [Abstract][Full Text] [Related]
5. [Genetic alterations and transformations in development and establishment of uterine endometrial carcinomas].
Inoue M
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Aug; 45(8):751-62. PubMed ID: 8371006
[TBL] [Abstract][Full Text] [Related]
6. Role of p53 and apoptosis in carcinogenesis.
Wang XW
Anticancer Res; 1999; 19(6A):4759-71. PubMed ID: 10697590
[TBL] [Abstract][Full Text] [Related]
7. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
8. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
9. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers.
Kahlenberg MS; Stoler DL; Basik M; Petrelli NJ; Rodriguez-Bigas M; Anderson GR
J Natl Cancer Inst; 1996 Nov; 88(22):1665-70. PubMed ID: 8931611
[TBL] [Abstract][Full Text] [Related]
10. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment.
Harris CC
Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):435-9. PubMed ID: 8781359
[TBL] [Abstract][Full Text] [Related]
11. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type.
Ranzani GN; Luinetti O; Padovan LS; Calistri D; Renault B; Burrel M; Amadori D; Fiocca R; Solcia E
Cancer Epidemiol Biomarkers Prev; 1995; 4(3):223-31. PubMed ID: 7606196
[TBL] [Abstract][Full Text] [Related]
15. Implications of the p53 tumor-suppressor gene in clinical oncology.
Chang F; Syrjänen S; Syrjänen K
J Clin Oncol; 1995 Apr; 13(4):1009-22. PubMed ID: 7707100
[TBL] [Abstract][Full Text] [Related]
16. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
17. Alterations of tumor suppressor genes in bladder cancer.
Cordon-Cardo C; Reuter VE
Semin Diagn Pathol; 1997 May; 14(2):123-32. PubMed ID: 9179973
[TBL] [Abstract][Full Text] [Related]
18. Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?
Fadare O; Roma AA; Parkash V; Zheng W; Walavalkar V
Adv Anat Pathol; 2018 Jan; 25(1):61-70. PubMed ID: 28945609
[TBL] [Abstract][Full Text] [Related]
19. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic significance of chromosome 17 aberrations and P53 gene mutations as prognostic markers in oral squamous cell carcinoma.
Zedan W; Mourad MI; El-Aziz SM; Salamaa NM; Shalaby AA
Diagn Pathol; 2015 Feb; 10():2. PubMed ID: 25881131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
